Investor Relations

Two bronchoscopes within the Ambu® aScope™ 5 Broncho portfolio have been cleared for pediatric use in the U.S. and Europe, extending Ambu’s Respiratory offering across both adult and pediatric patients.

Copenhagen, Denmark, 12 October 2026 – Ambu, the global market leader in single-use endoscopy, today announces that two bronchoscopes within its Ambu aScope 5 Broncho portfolio have received FDA 510(k) clearance and CE mark for use in pediatric airway procedures. The pediatric-indicated bronchoscopes are not yet commercially available.

The new indication extends Ambu’s bronchoscopy portfolio into pediatric care, strengthening the Company’s Respiratory offering across additional patient populations and clinical settings, including pediatric intensive care units, children’s hospitals, operating rooms, and emergency departments.

The two bronchoscopes, as well as a Sampler Set,  with expanded pediatric indication are:

• aScope 5 Broncho 2.7/1.2: For patients aged six months and older (the world’s first bronchoscope, including reusables, with a working channel for patients aged six months and older) 
• aScope 5 Broncho 4.2/2.2: For patients aged six years and older
• aScope 5 Broncho 4.2/2.2 Sampler Set: Cleared for patients aged six years and older

Due to lower procedure volumes and the specialized nature of pediatric care, clinicians often have limited access to pediatric bronchoscopes. When treating a particularly vulnerable patient population like pediatric patients, lack of bronchoscope availability can create workflow challenges and add pressure on caregiver teams. As a result, hospitals increasingly seek bronchoscopy solutions that can support both adult and pediatric patients, enabling them to address a broader range of clinical needs with a single solution.

By expanding into pediatric care, Ambu can now provide clinicians with immediate access to single-use bronchoscopes across both adult and pediatric patients, improving workflow efficiency and flexibility across care settings. Overall, the new pediatric indication strengthens the breadth of Ambu’s Respiratory offering and increases the relevance of the Company’s broader portfolio across both adult and pediatric care.

“This is an important step in extending the reach and value of our leading single-use Respiratory offering, in line with our ZOOM AHEAD strategy,” says Britt Meelby Jensen, CEO of Ambu. “With the pediatric indication, we can support clinicians across more procedures, patient groups, and care settings while reinforcing the value single-use solutions bring through improved availability, workflow efficiency, and patient care.” 

Ambu’s redesigned (internal design enhancements) pediatric bronchoscopy solutions are not yet available. Current Ambu aScope 5 Broncho solutions on the market are not cleared for pediatric use.

Ambu expects to initiate a commercial launch across the U.S. and Europe in early 2027.

 

Read the full press release here.

This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2026/27, as well as the date of Ambu’s Annual General Meeting. 
 

Deadline for the inclusion of specific items on the agenda for the Annual General Meeting 2026 is 20 October 2026.

Download the company announcement here.

Current Grifols CEO and former Olympus executive, Nacho Abia, brings more than 20 years of leadership experience across global healthcare and endoscopy.

Copenhagen, Denmark, 28 September 2026 – Ambu, the global market leader in single-use endoscopy, today announces that Jose Ignacio (Nacho) Abia Buenache has been appointed as an observer to Ambu’s Board of Directors and will be proposed for election as a member of the Board at the Company’s upcoming annual general meeting on 2 December 2026.

Nacho Abia currently serves as Chief Executive Officer and member of the Board of Directors of Grifols, a global pharmaceutical company with annual revenue exceeding EUR 7 billion.

Prior to joining Grifols in 2024, Abia spent more than two decades at Olympus Corporation, where he held several senior executive positions, including Global Chief Operating Officer, Chief Executive Officer of Olympus Americas, and Global Chief Strategy Officer.

“I am excited to welcome Nacho Abia as a board observer to Ambu’s Board of Directors,” says Jørgen Jensen, Chair of Ambu’s Board of Directors. “Nacho brings a strong combination of global healthcare leadership, endoscopy knowledge, and a proven track record of driving innovation, execution, and growth. His experience will be a significant asset to the Board as we continue to realize Ambu's substantial long-term potential.”

“Ambu is a pioneer in single-use endoscopy and has demonstrated how innovation, a strong culture, and close collaboration with clinicians can challenge established practices and create meaningful value for healthcare professionals and patients,” says Nacho Abia. “I believe Ambu is uniquely positioned to continue advancing endoscopy and expand the impact of single-use solutions globally. The company has a strong foundation, a clear strategic direction, and significant opportunities ahead. I look forward to working closely with the Board and Executive Management to support Ambu's continued growth and help shape the evolution of endoscopy.”

Read the press release here.